

AKORN INC  
Form 8-K  
February 28, 2019

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**Form 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event Reported): February 28, 2019

**Akorn, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Louisiana**

(State or Other Jurisdiction of  
Incorporation)

**001-32360**

(Commission File Number)

**72-0717400**

(I.R.S. Employer Identification  
Number)

**1925 W. Field Court, Suite 300, Lake Forest, Illinois  
60045**

(Address of Principal Executive Offices) (Zip Code)

**(847) 279-6100**

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  
]  
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  
]  
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  
]  
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  
]

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

---

**Item 2.02. Results of Operations and Financial Condition.**

On February 28, 2019, Akorn, Inc. (the “Company”) issued a press release announcing financial results as of and for the quarter and year to date period ended December 31, 2018. A copy of the press release is furnished as Exhibit 99.1 to this report.

The information in this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 7.01. Regulation FD Disclosure.**

The U.S. Food and Drug Administration (FDA) issued the Company a Form 483 dated February 13, 2019, related to an inspection of the Company’s Amityville, New York manufacturing facility in January and February of 2019. A redacted copy of the Form 483 is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

The information in this Item 7.01, including exhibit 99.2 attached hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

<u>Exhibit No.</u>	<u>Description of Exhibit</u>
<u>99.1</u>	<u>Press release dated February 28, 2018 entitled “Akorn Provides Fourth Quarter and Full Year 2018 Results.”</u>
<u>99.2</u>	<u>FDA Form 483 dated February 13, 2019 (redacted).</u>

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Akorn, Inc.**

Date: February 28, 2019

By: /s/ Duane A. Portwood  
Duane A. Portwood  
Chief Financial Officer